Special Issue

Exploring Environmental Risk Factors for Disease Progression in Multiple Sclerosis and Amyotrophic Lateral Sclerosis

Message from the Guest Editors

The objective of this Special Issue is to foster a comprehensive understanding of the environmental risk factors implicated in the progression of both multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Suitable topics include, but are not limited to, the following:

- Common Environmental Risk Factors: Toxic exposures, pollution, occupational hazards, smoking, physical activity, diet/nutrition, et al.
- Disease-Specific Environmental Risk Factors: Discuss environmental factors that are more specific to either MS or ALS, exploring their different role in disease onset and progression and potential mechanisms of action.
- Biomarkers and Mechanisms: Explore biomarkers or underlying mechanisms that are implicated in both diseases, shedding light on potential pathways that link environmental exposures to disease progression.
- Preventive Strategies and Interventions: This may involve lifestyle modifications, public health policies, pharmacological interventions, and innovative technologies.



Dr. Maurizio A. Leone

 Scientific Direction, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy

Dr. Radu Tanasescu

Division of Clinical Neuroscience, Section of Clinical Neurology, University of Nottingham, Nottingham NG7 2UH, UK

Deadline for manuscript submissions

20 February 2026



Sclerosis

an Open Access Journal by MDPI



mdpi.com/si/203886

Sclerosis Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 sclerosis@mdpi.com

mdpi.com/journal/

sclerosis





Sclerosis

an Open Access Journal by MDPI



sclerosis



About the Journal

Message from the Editor-in-Chief

Welcome to Sclerosis.

Sclerosis is a term that encompasses various conditions that involve the stiffening and scarring of tissues and organs. It is a pathologic process of some highly prevalent diseases, such as multiple sclerosis, glomerulosclerosis, atherosclerosis, and more rare diseases, such as amyotrophic lateral sclerosis, systemic sclerosis, and tuberous sclerosis. *Sclerosis* aims to provide a platform for dissemination of cutting-edge research and clinical practice in the field. Looking to similarities and differences among "sclerotic" diseases, we aim at identifying shared pathological mechanisms and risk factors, management pathways, and drugs with repurposing potential, while also exploring preventive and therapeutic strategies.

Editor-in-Chief

Dr. Maurizio A. Leone

1. Scientific Direction, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

2. Istituto di Ricerche Farmacologiche "Mario Negri", Milano, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 37.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.